Meriofert

Follicle‑Stimulating Hormone; Luteinising Hormone, the active ingredient in Meriofert, is a gonadotropin presented as an injectable solution for intramuscular or subcutaneous use. It is used to stimulate ovarian follicular development and ovulation in women with infertility due to anovulation. GNH USA supplies Meriofert as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Meriofert, a gonadotropin used in reproductive medicine, is indicated for the following conditions:

- Infertility due to anovulation: promotes follicular growth and ovulation in women who do not ovulate spontaneously. - Controlled ovarian stimulation for assisted reproductive technologies: supports development of multiple follicles to obtain oocytes for IVF or ICSI. - Oocyte donation cycles: enables safe ovarian stimulation in egg donors to retrieve mature oocytes for donation programs.

Meriofert may cause a range of adverse reactions. Monitoring and patient counseling are essential.

Common Side Effects: - Injection site pain or erythema: mild discomfort at the injection site. - Abdominal bloating or discomfort: transient gastrointestinal symptoms. - Nausea or mild vomiting: usually self‑limited. - Headache: may occur during early treatment. - Mild ovarian hyperstimulation: enlarged ovaries without severe symptoms. - Mood changes: occasional irritability or emotional lability.

Serious or Rare Side Effects: - Ovarian hyperstimulation syndrome (severe): rapid weight gain, ascites, respiratory distress. - Multiple pregnancy: increased risk of twins or higher‑order gestations. - Thromboembolic events: deep vein thrombosis or pulmonary embolism. - Anaphylactic reaction: severe allergy requiring immediate medical attention. - Ectopic pregnancy: implantation outside the uterine cavity. - Severe abdominal pain: may indicate ovarian torsion or rupture.

Before initiating Meriofert therapy, several safety considerations should be observed.

- Pregnancy testing: confirm non‑pregnant status prior to treatment. - Ovarian monitoring: perform serial ultrasound to assess follicular response. - Risk of OHSS: educate patients on signs of ovarian hyperstimulation syndrome and intervene promptly. - Multiple gestation counseling: discuss increased likelihood of twins or higher‑order pregnancies. - Hypersensitivity assessment: verify no known allergy to gonadotropin preparations. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Meriofert can interact with other medications that affect reproductive hormones or coagulation.

Major Interactions (Avoid): - GnRH antagonists: may diminish the efficacy of Meriofert. - Oral contraceptives: suppress endogenous gonadotropins, reducing response. - High‑dose estrogen therapy: can interfere with follicular stimulation.

Moderate Interactions (Monitor Closely): - Thyroid hormone replacement: adjust dosing if thyroid status changes. - Anticoagulants: monitor for thrombosis risk if severe OHSS develops. - Corticosteroids: may alter ovarian response, requiring dose adjustment.